Exicure, Inc. (XCUR) Stock Score, Valuation & Financial Research

Exicure, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for XCUR

Exicure, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.08. These figures are a research snapshot, not a buy or sell recommendation.

What Exicure, Inc. does

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Exicure, Inc. is a biotechnology company that has historically focused on developing nucleic acid therapies. Following a restructuring and the suspension of its clinical and development activities, the company is currently exploring strategic alternatives to maximize stockholder value and has acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases.

Products and services

  • The company is currently in a transition phase, having suspended its previous clinical and development activities, and is exploring strategic alternatives following the acquisition of a clinical-stage biotechnology company.

Business strengths to evaluate

  • Exploration of strategic alternatives to maximize stockholder value Source

Business risks and research considerations

  • History of operating losses and uncertainty regarding future financing Source
  • Risks associated with the ability to successfully execute strategic alternatives Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

XCUR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.08
Market capitalization:
6.88M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -8.28M
Free cash flow:
USD -8.56M
Cash:
USD 1.72M
Total debt:
USD 176K
EPS:
USD -1.31

What stands out

  • Free cash flow is USD -8.56M, negative for the stored period.
  • The balance sheet shows USD 1.72M of cash versus USD 176K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.54M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for XCUR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can XCUR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is XCUR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for XCUR to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of XCUR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research XCUR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.